Canaccord Genuity Reiterates Buy on BioNTech, Maintains $203 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Bill Selesky reiterates a Buy rating on BioNTech (NASDAQ:BNTX) and maintains a $203 price target.
June 16, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst maintains Buy rating on BioNTech (NASDAQ:BNTX) with a $203 price target.
The reaffirmed Buy rating and maintained price target by Canaccord Genuity analyst Bill Selesky indicates a positive outlook for BioNTech's stock. This news is likely to have a positive short-term impact on BNTX's stock price as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100